| Paul Cary Aguillard, MD | |
|
1702 N Burnside Ave, Gonzales, LA 70737-2141 | |
| (225) 647-8319 | |
| (225) 644-5213 |
| Full Name | Paul Cary Aguillard |
|---|---|
| Gender | Male |
| Speciality | Pediatric Medicine |
| Experience | 32 Years |
| Location | 1702 N Burnside Ave, Gonzales, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871591982 | NPI | - | NPPES |
| 1984329 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 09731R (Louisiana) | Secondary |
| 208000000X | Pediatrics | 09731R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Our Lady Of The Lake Regional Medical Center | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Our Lady Of The Lake Physician Group Llc | 4587849781 | 521 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
| Entity Name | Our Lady Of Lake Ascension, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306899067 PECOS PAC ID: 3577452259 Enrollment ID: O20040311000822 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
| Entity Name | Hospital Service District No 1 Of Pointe Coupee |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588648315 PECOS PAC ID: 4688610223 Enrollment ID: O20050705000687 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
| Entity Name | Our Lady Of The Lake Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033494943 PECOS PAC ID: 4587849781 Enrollment ID: O20120529000377 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
| Entity Name | C & M Hospitalist Group,llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548652019 PECOS PAC ID: 8224355680 Enrollment ID: O20150323002295 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Cary Aguillard, MD 1702 N Burnside Ave, Gonzales, LA 70737-2141 Ph: (225) 647-8319 | Paul Cary Aguillard, MD 1702 N Burnside Ave, Gonzales, LA 70737-2141 Ph: (225) 647-8319 |
News Archive
New research may be useful for protecting against the toxic effects of snake venom. Investigators have identified the specific protein that's targeted by snake venom and causes cells to detach from each other and induce internal bleeding.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that between December 8, 2010 and February 9, 2011 it entered into agreements with certain accredited investors, pursuant to which the Company sold to the purchasers in the aggregate approximately $7.8 million of the Company's Series D convertible preferred stock, which is convertible into shares of common stock at a conversion price of $0.50 per share.
The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function (ejection fraction). The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether this drug combination offers an added benefit for patients in comparison with the appropriate comparator therapy.
This fall, the University of Pennsylvania's Basser Research Center for BRCA is taking its lifesaving efforts to raise awareness about hereditary breast and ovarian cancers on the road and into synagogues across the country.
Every year, more than a million Americans receive an artificial hip or knee prosthesis. Such implants are designed to last many years, but in about 17 percent of patients who receive a total joint replacement, the implant eventually loosens and has to be replaced early, which can cause dangerous complications for elderly patients.
› Verified 7 days ago
Dr. Brittany Alexis Landry, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2400 S Burnside Ave, Gonzales, LA 70737 Phone: 225-761-5200 Fax: 225-709-6425 | |
Cammie A Hilliard, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1937 S Burnside Ave, Gonzales, LA 70737 Phone: 225-765-5500 Fax: 225-644-9286 | |
Leyamma Mathew, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 721 E Highway 30, Gonzales, LA 70737 Phone: 225-644-7337 Fax: 225-644-5202 | |
Mrs. Allison Renee Dupuis Prevost, M. D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2647 S Saint Elizabeth Blvd Ste 320, Gonzales, LA 70737 Phone: 225-647-8511 Fax: 225-647-5093 | |
Sarah Wilks, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1702 N Burnside Ave Ste C, Gonzales, LA 70737 Phone: 225-765-5500 Fax: 225-644-0341 | |
Dawn Zitman, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1937 S Burnside Ave, Gonzales, LA 70737 Phone: 225-765-5500 Fax: 225-644-9286 | |
Tracy Wallace, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1937 S Burnside Ave, Gonzales, LA 70737 Phone: 225-765-5500 Fax: 225-644-9286 |